The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Search
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
The NCD Initiative | Infographic
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag
Championing Novel Science
Championing Novel Science
COVID-19
COVID-19
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies
World Water Day 2019 | Boehringer Ingelheim US
Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
Work life wellness
We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
The Evolution of Biologic Medicines
Biotherapeutics Modalities Infographic
For Your SweetHeart | Infographic
Partnering-Biotherapeutics.pdf
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
Diabetes
Diabetes
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
What to Expect from Your Vaccine | Boehringer Ingelheim US
Read more on how horse owners are encouraged to schedule a wellness exam with their veterinarians, including annual equine vaccinations.
Why role models matter for black veterinarians: One doctor's story
Why role models matter for black veterinarians: One doctor's story
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US
Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).